Sanctuary Advisors LLC bought a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 370,246 shares of the company’s stock, valued at approximately $47,577,000.
Several other hedge funds and other institutional investors also recently modified their holdings of MKGAF. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Merck KGaA during the 2nd quarter valued at approximately $942,087,000. Bank of Nova Scotia bought a new position in Merck KGaA in the 2nd quarter worth approximately $281,696,000. Danske Bank A S purchased a new position in Merck KGaA in the 2nd quarter valued at approximately $276,535,000. Korea Investment CORP bought a new stake in Merck KGaA during the 2nd quarter valued at $239,191,000. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Merck KGaA during the second quarter worth $183,444,000. Institutional investors own 0.10% of the company’s stock.
Merck KGaA Stock Performance
OTCMKTS:MKGAF opened at $163.21 on Monday. Merck KGaA has a 1 year low of $116.68 and a 1 year high of $175.56. The stock’s fifty day moving average price is $162.62 and its two-hundred day moving average price is $148.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The company has a market cap of $21.09 billion, a P/E ratio of 24.92 and a beta of 0.96.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
